Boehringer Ingelheim and DeveloGen AG : agreement in the field of diabetes, obesity and the metabolic syndrome

May 13th, 2009 - Boehringer Ingelheim and DeveloGen AG, announced the signing of an asset sale and purchase and collaboration agreement in the field of diabetes, obesity, the metabolic syndrome and other insulin resistance associated disorders...

...


About DeveloGen
DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine diseases. The Company has a highly innovative and deep preclinical discovery pipeline addressing the key drivers in the development of diabetes and obesity such as insulin resistance and loss of insulin-producing beta cells...

...



About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees... [PDF] DeveloGen's Press Release - Boehringer Ingelheim's Press Release -